Compumedics Limited engages in the research, development, manufacturing, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Okti; Grael PSG; Grael DC; Falcon HST; Somté, an investigative tool; and Somté PSG. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, an portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, the company provides software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, TCM5 FLEX transcutaneous monitors, and persyst software products. Further, it provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Stock data | 2023 | Change |
---|---|---|
Price | $0.20121399107951304 | N/A |
Market Cap | $35.65M | N/A |
Shares Outstanding | 177.16M | 4.44% |
Employees | 135.00 | N/A |
Shareholder Equity | 18.29M | -22.47% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 1.25 | N/A |
P/B Ratio | 1.95 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.2245 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $28.44M | N/A |
Earnings | -$4.11M | N/A |
Gross Margin | 0.5091 | N/A |
Operating Margin | -0.1072 | N/A |
Net income margin | -0.1444 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $27.62M | N/A |
Total Debt | $6.35M | N/A |
Cash on Hand | $2.55M | N/A |
Debt to Equity | 0.8394 | 62.95% |
Cash to Debt | 0.4011 | -63.99% |
Current Ratio | $1.39 | -27.16% |